Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IMMUNOCHEMOTHERAPY OF METASTATIC UVEAL MELANOMA WITH INTERFERON-ALPHA-2B, INTERLEUKIN-2, AND FOTEMUSTINE - CASE-REPORTS AND LITERATURE-REVIEW
Autore:
TERHEYDEN P; KAMPGEN E; RUNGER TM; BROCKER EB; BECKER JC;
Indirizzi:
UNIV KLINIKUM WURSBURG,JOSEF SCHNEIDER STR 2 D-97080 WURZBURG GERMANY UNIV WURZBURG,HAUT KLIN WURZBURG GERMANY UNIV GOTTINGEN,HAUT KLIN D-3400 GOTTINGEN GERMANY
Titolo Testata:
Hautarzt
fascicolo: 10, volume: 49, anno: 1998,
pagine: 770 - 773
SICI:
0017-8470(1998)49:10<770:IOMUMW>2.0.ZU;2-6
Fonte:
ISI
Lingua:
GER
Soggetto:
OCULAR MELANOMA; MALIGNANT-MELANOMA; EXPRESSION; LIVER; SURVIVAL;
Keywords:
UVEAL MELANOMA; METASTASES; FOTEMUSTINE; INTERLEUKIN-2; INTERFERON-ALPHA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
P. Terheyden et al., "IMMUNOCHEMOTHERAPY OF METASTATIC UVEAL MELANOMA WITH INTERFERON-ALPHA-2B, INTERLEUKIN-2, AND FOTEMUSTINE - CASE-REPORTS AND LITERATURE-REVIEW", Hautarzt, 49(10), 1998, pp. 770-773

Abstract

In spite of their tumor's origin in the uveal tract, many patients suffering from advanced uveal melanoma are admitted to dermatological oncology units. Most patients with metastases from uveal melanoma receive treatments that were established for stage IV cutaneous melanoma. However, both the biology as well as the metastastic behaviour of this tumor is different from cutaneous melanoma. Lymphatic metastases do notoccur,and hematogeneous metastases usually occur later and predominantly involve the liver. The prognosis is very bad ranging from 2 to 5 months. We describe three patients with advanced uveal melanoma who received immunochemotherapy containing interferon-alpha 2b, interleukin-2, and fotemustine. This therapy induced a partial response of more than 49 months duration in one patient,whereas for the remaining patientsthe disease progression could be stabilized for eight and 16 months, respectively. This therapeutic success is reflected by a prolonged survival of 14, 43+, and 59+ months.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 16:05:56